EUVIMEDEUVIMED entdecken
Open Access

Acceptability of a 250 mg levofloxacin formulation in children receiving TB preventive treatment

S E Purchase, J Brigden, J A Seddon, N A Martinson, L Fairlie, S Staples, A Poswa, T Duong, H S Schaaf, A C Hesseling

IJTLD Open · 2025-03 · 2 (3) · 129-136

DOI: 10.5588/ijtldopen.24.0569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IJTLD Open, online erschienen am 01.03.2025. Verfasst von S E Purchase und 9 weiteren Autor:innen. Beteiligte Einrichtung: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Sout…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Recent evidence indicates that levofloxacin (LFX) is effective in preventing TB in individuals exposed to multidrug-resistant TB (MDR-TB). Despite the need for pediatric formulations, the 250 mg adult LFX formulation is affordable and widely used for TB treatment and prevention in children. METHODS TB-CHAMP (Tuberculosis Child Multidrug-resistant Preventive Therapy ISRCTN92634082 ) was a trial of MDR-TB preventive treatment, comparing levofloxacin to placebo in children with MDR-TB exposure. Acceptability questionnaires were administered to caregivers at six timepoints during the 24-week treatment phase. Likert scales were used to grade 6 domains of acceptability, and a composite acceptability (CA) outcome was generated. Factors associated with acceptability were assessed using modified Poisson regression models to estimate risk ratios (RRs). RESULTS Overall, 922 children were randomised, 453 to LFX and 469 to placebo. By Week 8, 25.1% of children on LFX had poor CA versus 6.2% receiving placebo (Weeks 0–24: RR 3.43, 95% CI 2.69–4.37). Acceptability in the LFX arm improved from 36.8% poor CA at baseline to 12.9% at Week 24. Only 11.7% of children swallowing tablets whole/halved had poor CA outcomes at Week 8, compared to 34.4% swallowing crushed/softened tablets. CONCLUSION LFX 250 mg tablets have reasonable acceptability and could be used as an alternative to dispersible formulations, especially in children able to swallow tablets.

Schlagwörter

Stichwörter der Autor:innen

multidrug-resistant tuberculosispaediatricsprevention

Autor:innen und Institutionen

  • Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
  • Institute of Clinical Trials and Methodology, MRC Clinical Trials Unit at University College London, London, UK.
  • Department of Infectious Disease, Imperial College London, London, UK.
  • Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
  • Johns Hopkins University Center for TB Research, Baltimore, MD, USA.
  • Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Förderung

  • Wellcome Trust

Zitieren

APA

Purchase, S. E., Brigden, J., Seddon, J. A., Martinson, N. A., Fairlie, L., Staples, S., Poswa, A., Duong, T., Schaaf, H. S., & Hesseling, A. C. (2025). Acceptability of a 250 mg levofloxacin formulation in children receiving TB preventive treatment. IJTLD Open, 2(3), 129-136. https://doi.org/10.5588/ijtldopen.24.0569

Vancouver

Purchase SE, Brigden J, Seddon JA, Martinson NA, Fairlie L, Staples S, et al. Acceptability of a 250 mg levofloxacin formulation in children receiving TB preventive treatment. IJTLD Open. 2025;2(3):129-136. doi:10.5588/ijtldopen.24.0569

BibTeX
@article{Purchase2025,
  author = {Purchase, S E and Brigden, J and Seddon, J A and Martinson, N A and Fairlie, L and Staples, S and Poswa, A and Duong, T and Schaaf, H S and Hesseling, A C},
  title = {Acceptability of a 250 mg levofloxacin formulation in children receiving TB preventive treatment},
  journal = {IJTLD Open},
  year = {2025},
  volume = {2},
  number = {3},
  pages = {129--136},
  doi = {10.5588/ijtldopen.24.0569}
}
Kostenlos starten →